Challenging and Defending BioPharma Patents at the PTAB - What Practitioners Need to Know

To access a recording of this webinar or receive a copy of the slides, please contact [email protected].

IPR and CBM petitions present unique opportunities and issues in the biopharma area for both branded and generic companies. The number of petitions being filed in this area is growing steadily. Listen in as we explored strategic issues related to post-grant practice, Hatch-Waxman litigation, and biosimilars.